Pathways of IFN-alpha Activation in Patients with Cervical Intraepithelial Neoplasia (CIN)

Vias de ativação de IFN-alfa em pacientes com Neoplasia Intraepitelial Cervical (NIC)

Nelson Ranieri Tirone1 Carolina Guissoni Campos1 Kézia Jesus Aguiar Ferreira1 Léticia Montes Stark1 Jéssica Ferreira Vieira1 Eddie Fernando Cândido Murta1,2 Márcia Antoniazi Michelin1,3

1Instituto de Pesquisa em Oncologia, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil
2Department of Gynecology and Obstetrics, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil
3Discipline of Immunology, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil

Address for correspondence Márcia Antoniazi Michelin, Professor, Discipline of Immunology, Instituto de Pesquisa em Oncologia, Universidade Federal do Triângulo Mineiro, Avenida Guilherme Ferreira, 1940, 38022-200, Uberaba, MG, Brazil (e-mail: marcia.michelin@uftm.edu.br).

Rev Bras Ginecol Obstet 2021;43(9):682–689.

Abstract

Objective The aim of the present study was to compare the local and systemic expression of the factors linked to the interferon alpha (IFN-α) activation pathway in different degrees of cervical intraepithelial neoplasia (CIN) and cervical cancer.

Methods A total of 128 patients with CIN I, CIN II, CIN III and cervical cancer was evaluated. The real-time polymerase chain reaction (RT-PCR) technique was used to evaluate the gene expression of IFNR1, IFNR2, IFN-α, oligoadenylate synthase (2’5’OAS), cytokine signal suppressor 1 (SOCS) 1, SOCS3, signal transducer and transcription activator 1 (STAT1), and IRF9 from 128 biopsies. A total of 46 out of 128 samples were evaluated by flow cytometry for IFNAR1, IFNAR2, STAT1, IRF7 and IFN-α in peripheral blood cells.

Results Patients with CIN II and III (63 samples) had a low local expression of IFNR1, but not IFNR2. Patients with some degree of injury showed high expression of SOCS1 and SOCS3. Systemically, patients with CIN II and III (20 samples) had a significant increase in IFNR1, IFNR2, STAT1, IRF7, and IFN-α in helper, cytotoxic T lymphocytes, and in monocytes.

Conclusion Patients with high-grade lesions have increased systemic expression of IFN-α and its activation pathways in helper and cytotoxic T lymphocytes, as well as in monocytes due to an exacerbation of the immune response in these patients. This phenomenon is not accompanied by resolution of the lesion due to a defect in the IFN-α activation pathway that revealed by low local IFNAR1 expression and high local expression of SOCS1 and SOCS3.

Keywords
► interferon receptors
► cervical
► intraepithelial neoplasia
► interferon alpha

received December 10, 2020
accepted August 2, 2021

DOI https://doi.org/10.1055/s-0041-1735301.
ISSN 0100-7203.

© 2021. Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited.
(https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Pathways of IFN-alpha Activation in Patients with Cervical Intraepithelial Neoplasia

Tirone et al.

Introduction

The possibility of early screening and treating neoplastic lesions was of considerable importance in reducing the incidence and deaths from invasive cervical cancer. Cervical intraepithelial neoplasms (CIN), which are preinvasive lesions, have different degrees. Grade I should be treated to preserve the cervix, while for grades II and III, local excision of the cervix has been considered as a therapeutic intervention because the latter has the potential for progression to invasive cancer (CA). However, this imposes risks during pregnancy, such as increased prematurity and abortions.

Thus, alternatives for treatment have been evaluated, such as the use of interferons (IFNs), which have been recognized as extremely important cytokines for human health, since they have therapeutic potential against viral actions. As a fundamental part of the immune response, interferon alpha (IFN-α) is able to inhibit exacerbated cell proliferation through its signaling pathways. It is also able to suppress the expression of oncoproteins and to promote apoptosis.

A Janus kinase/tyrosine kinase (JAK/TYK) signaling cascade is activated when IFN-α binds to specific interferon receptors (IFNR1 and IFNR2). This results in the generation of interferon-stimulated genes (ISGs). Viral clearance begins with peripheral immune cells alerted by the cell in an antiviral state, along with transcription factors.

Transcription factors can act in the regulation of the cell cycle, apoptosis, and body defense. They are also present in homeostasis and immune cell development and are related to oncogenesis. As an example of transcription factors are the signal transducer and transcription activator (STAT) and interferon regulatory factor (IRF) family. In addition, there are the regulators of the signaling pathways in the cellular machinery orchestrated by IFN-α. The cytokine signal suppressor (SOCS) is composed of SOCS1-SOCS7. Involved in the negative regulation of JAK/STAT signaling, the SOCS suppresses endogenous and prognostic signaling of IFN-α by viral infection.

Thus, the aim of the present study was to compare the expression of factors directly linked to the IFN-α activation pathway in different degrees of CIN and cervical cancer, locally and systemically, by flow cytometry and molecular analysis.

Methods

Research Subjects

The present study included women between 18 and 50 years old with CIN I (n = 45), CIN II (n = 30), CIN III (n = 33), and cervical cancer (n = 20). The inclusion criteria were absence of bleeding during the exam, no use of oral antibiotics, fungicides, or vaginal creams in the last 30 days; no sexual activity for at least 2 days before the collection day; and with no previous history of treatment for human papillomavirus (HPV). Patients with negative pathological results for CIN and HPV were included in the controls. All procedures performed followed the criteria proposed by the Research Ethics Committee (CEP, in the Portuguese acronym) under the protocol...
For local analysis, biopsies were collected and stored in TRIzol (Invitrogen, Waltham, MA, USA) for subsequent RNA extraction and analysis via real-time polymerase chain reaction (RT-PCR) for the analysis of IFNR1, IFNR2, oligoadenylate synthase (2′S-OAS), IFN-α, STAT1, IRF9, SOCS1, and SOCS3. For the systemic analysis, peripheral blood was collected for verification by flow cytometry of IFNR1, IFNR2, IFN-α, STAT1, and IRF7.

**Flow Cytometry**
Peripheral blood (PB) samples from the patients were taken and the cells were evaluated by flow cytometry (BD FACS Calibur TM cytometer, BD Biosciences, San Diego, CA, USA). The cytometry protocols were implemented according to those suggested by the manufacturer. Peripheral blood cells were evaluated for the following markers: CD3+CD4+ (T helper lymphocytes), CD3+CD8+ (T CTL lymphocytes), and CD14+ (monocytes).

Leukocytes were isolated from PB samples by centrifugation at 4°C, following the instructions of the manufacturer (FACS Lysing Solution, BD Biosciences, Franklin Lakes, NJ, USA). The cells were resuspended in phosphate-saline solution (PBS) for extracellular marking with anti-CD3, anti-CD4, anti-CD8 or anti-CD14. For intracellular labeling, the cells were incubated with the following antibodies labeled with IFNR1, IFNR2, IFN-α, STAT1 or IRF7.

In all experiments and in all patients, we used intracellular and extracellular negative control isotopes using fluorochrome conjugated antibodies according to the reference antibody. After intracellular staining, the cells were incubated at 4°C for 30 minutes and resuspended in 500µL of PBS for cytometric analysis in the cytometer. For the specific determination of cells corresponding to lymphocytes and macrophages, we identified the region to be analyzed by the construction of gates according to controls of relative size (direct dispersion; FSC) and granularity and complexity (lateral dispersion; SSC) in each experiment and for each patient.

**RT-PCR – Reverse Transcription and Polymerase Chain Reaction**
The RNA was extracted from cervical biopsies using TRizol reagent. cDNA synthesis was performed with Superscript III rt (Invitrogen, Waltham, MA, USA). Conventional PCR was performed with the PCR mixing solution (Invitrogen, Waltham, MA, USA). The samples were taken to a thermal cycler with the following programming: initial denaturation at 94°C for 3 minutes; amplification of 40 cycles at 94°C for 1 minute (denaturation), annealing temperature for 1 minute (hybridization) and at 72°C for 1 minute (polymerization); final polymerization: 72°C for 10 minutes. At the end of the amplification cycles, the reaction was stopped by cooling to 4°C. Primer sequences used were: Beta-actin, (F) 5′-AGG GCT TCC TTC TAG GAC GG-3′, (R) 5′-GGG GCC CCA AAT GGT TTT CGG-3′, 56° C, 295 bp; IFN1, (F) 5′-CTT AAT GTC ACC TGG CTT CCT CGG-3′, (R) 5′-TCA CAG GCG TGT TTC CAC ACT G-3′, 57° C, 500 bp; IFNR2, (F) 5′-GAA GTT TAA GAA CTG GC-3′, (R) 5′-CCC GCT GT TCC TTC TAG GAC GG-3′, 57° C, 105 bp; IFN-α, (F) 5′-ACT TGT GAT TCC CCC CAG GA-3′, (R) 5′-CAG CCAC GGC GTG TAT TT-3′, 59° C, 316 bp; SOCS1, (F) 5′-AGG AGC ATC CGG GTG CAG CCC AAC-3′, (R) 5′-AAG AGG CAC TAG AAG CTC TCC-3′, 64° C, 90 bp; SOCS4, (F) 5′-GAA GAT CCT TGG GTT GA-3′, (R) 5′-TTC CCA CAG AGA TGC TGA AGA GT-3′, 63° C, 70 bp; STAT1, (F) 5′-AGG AAG AAC CAC AGC CAA TGG AAC-3′, (R) 5′-GAG CCC ACT ATC CGA GAC TCC-3′, 59° C, 150 bp; IRF9, (F) 5′-AGA GGA TTC TCT GCA GAA GAT CC-3′, (R) 5′-GCT CCC AAT TGC TGA ATG GAC-3′, 63° C, 110 bp; 2′S-OAS, (F) 5′-ACC TGG TTC CTT TCT TCA TCC C-3′, (R) 5′-GAG CTT CCT CATCAA ACT TCA C-3′, 54° C, 200 bp.

To visualize the products amplified by the RT-PCR reactions, the samples were submitted to 10% polyacrylamide gel electrophoresis. Then, the gels were stained with silver nitrate. A positive standard control of 50 bp DNA Invitrogen ladder was used.

**Statistical Analysis**
An electronic database was developed for statistical analysis. The variables were analyzed using GraphPad Prism 8.4 (GraphPad Software, San Diego, CA, USA). The values were subjected to the chi-squared statistical test for PCR and to the Kruskal-Wallis test with the Dunn post-test for cytometry values. Differences with $p \leq 0.05$ were considered statistically significant.

**Results**
A systemic analysis of the receptors and transcription factors expressed in different cell populations was carried out to better understand the cell activation process of the studied groups. The mean fluorescence intensity (MFI) was observed for T CTL lymphocytes (CD8+), T helper lymphocyte (CD4+), and monocytes (CD14+) (∆ Figure 1).

The MFI for IFN-α was higher in monocytes. When comparing the different study groups by cell type, a significant increase in CIN II and CIN III was observed in relation to Control in the populations of CD4+ ($p=0.0005$), CD8+ ($p<0.0001$), and monocyte cells/CD14+ ($p=0.0029$) (∆ Figure 1A).

For the IFNR1 and IFNR2 receptors (∆ Figure 1B, C), in each cell population compared (CD4+, CD8+, and CD14+), the IFNR1 and IFNR2 receptors were increased in the CIN II and CIN III groups compared to the Control group IFNR1+ CD4+ ($p=0.0002$); IFNR1+ CD8+ ($p=0.0011$); IFNR1+ CD14+ ($p=0.0011$); IFNR2+ CD4+ ($p=0.0003$); IFNR2+ CD8+ ($p<0.0001$); and IFNR2+ CD14+ ($p=0.0009$).

Transcription factors were also analyzed in the T helper lymphocytes, T CTL lymphocytes, and monocytes (∆ Figure 2). We observed a significant increase in CIN II and CIN III compared to the Control group (∆ Figure 2A) for both STAT1 ($p=0.0031$) and IRF-7 ($p=0.0008$). The T helper and T CTL lymphocytes had a lower MFI than the monocyte population. We observed a significant increase in IRF7+ in the CIN II and CIN III groups compared to the Control group in the population of CD4+ and CD8+ cells in the IRF-7: IRF-7+ CD4+ ($p=0.0002$); IRF-7+ CD8+ ($p<0.0001$). Regarding STAT1, we observed a significant increase in CIN I, CIN II, and CIN III.
compared to Control for the two cell populations evaluated (CD4+ and CD8+) \( (p = 0.0350) \) (► Figure 2B, C) in the CD8+, STAT1+CD4+ \( (p = 0.0003) \); and STAT1 + CD8+ \( (p < 0.0001) \) populations.

Analyzing the local expression of IFN-alpha receptors and transcription factors, it was found that the IFNR2 receptor was expressed in approximately 70% of patients in the control groups, CIN I, CIN II and Invasive Cancer. Statistically significant, the IFNR1 receptor was expressed in approximately 10% of patients in the CIN II and CIN III groups. The control group showed no expression for IFN-alpha and the expression for the enzyme 2’5’OAS showed no difference between the groups (► Figure 3A). The expression of the IFNR2 receptor can be observed with the presence of a fragment of molecular weight 105bp for positive patients (► Figure 3B).

Transcription factors linked to IFN-α cell activation were observed for sites in each group. It was observed...
that SOCS1 was expressed in 100% of the samples evaluated from the four study groups (CIN I, CIN II, CIN III, and Invasive). SOCS 3 was expressed in 95% of the samples evaluated in the Invasive group; approximately 60% in the CIN III and CIN II groups, and approximately 55% in the CIN I. STAT1 was expressed in approximately 90% of the samples in the Invasive group, ~50% in CIN III, ~80% in CIN II, and ~70% in CIN I. And IRF9 was expressed in ~45% of the samples from the Invasive group and ~20% in the other groups (CIN III, CIN II, and CIN I) had a higher percentage of patients who expressed all transcription factors (~Figure 4).

Fig. 2. Mean intensity of flowering (MFI) in the CD14+, CD8+, and CD4+ populations of STAT1+ and IRF-7+. A. IFN-α MFI in Control, NICII, NICIII and Invasive groups in the three cell populations. B. IFNRI receptor MFI in the Control NICII, NICIII and Invasive groups in the three cell populations. C. IFNRII receptor MFI in the Control NICII, NICIII and Invasive groups in the three cell populations. The results were analyzed using the Kruskal-Wallis test with the Dunn post-test in GraphPad Prism 8.4. For the comparisons Control x CIN II and Control x CIN III in the graphs, significance was observed, with p < 0.05 (5%). Values represented in median (min-max).
According to the analyzes performed, IFNR1 and IFNR2 were expressed in different ways in the cell subtypes analyzed in PB by flow cytometry. Literature data show that the concentration of the receptor on the cell surface and that the organization of the cell in space are important parameters that can cause different responses to IFN-α in individuals. 

RT-PCR analyzes demonstrate a decrease in the expression of IFNR1 and IFNR2 in lesions, as the lesion progresses from CIN I to CIN III, with the expressions being reduced in relation to the non-existence of the lesion (Control group). However, its expression is increased in Invasive. In a previous study carried out in our group, it was observed that IFNR1 and IFNR2 (mRNA) were poorly expressed in neoplastic biopsies when compared with control biopsies. 

According to the guidelines that regulate cervical biopsies, such as the International Federation of Gynecology and Obstetrics, women with altered cytological and colposcopic results with suspicion of high-grade HPV or justifiable disease, are submitted to biopsies. Thus, a disease-free control group could not be included in our study because women without colposcopic changes are not submitted to biopsy, an important condition for inclusion in the studied groups.

The density of receptors on the cell surface and the binding affinity of the IFN-α subtypes with them are directly related to the different responses triggered by the cytokine binding with the receptor. Therefore, it may be that the number of women who expressed the receptors in the group of CINIII lesions and invasive carcinoma was not enough to generate a local IFN-α response.

The present study demonstrated that during the evolution of the neoplastic lesion, no alterations in the expression of IFN-α were observed. The same can be observed in a study that showed no gene expression of IFN-α in Control samples. However, data from the literature demonstrate that IFN may be increased in viral infections and demonstrate the various ways in which HPV oncoproteins interfere with
the IFN-alpha activation system, interacting with signaling and signal transduction pathways and inhibiting the activation of transcriptional factors. Recently, the function of the E5 protein, which can suppress IFN signaling, was discovered.\textsuperscript{17}

Our data also show that the CINI group has a high expression of STAT1 and SOCS1 and a low expression of IFNR1. The SOCS1 can exert an antitumor function by regulating chronic inflammation and mediating the phosphorylation of the tumor suppressor protein p53.\textsuperscript{18}

Our data also showed that, with the progression of the lesion, a decrease in the expression of SOCS3 is observed. In another study, a similar situation was demonstrated; however, regarding HPV positivity: a reduction in the expression of SOCS and SOCS3 in HPV positive tumors, whereas, in HPV negative tumors, the expression of SOCS was similar to that of the healthy control group. This negative regulation of SOCS can be mediated by HPV.\textsuperscript{19}

It was also possible to observe that an MFI by STAT1 flow cytometry was higher in the population of TCL than in the other studied populations. In an assay performed with HeLa cells, in which endocytosis of the IFNAR receptor was blocked, an insufficient presence of STAT1 was observed in the nucleus, and even after IFN-α stimulation the transcriptional performance dependent on this cytokine was inhibited. Therefore, blocking the endocytosis of IFNAR is likely to prevent the transcription of activated genes in advance, among which are essential genes to initiate antiviral and antiproliferative functions.\textsuperscript{20}

The presence of HPV alone in the uterine cervix can be an adjuvant in the negative regulation of IFNR1, being related to the different systemic and local expressions. Some factors, such as smoking, immune response, sexual behavior, multiple HPV infections, and viral load, are related to the progression from low-grade lesions to high-grade lesions. It is known that HPV can induce cell polarization for the anti-inflammatory profile through the production of cytokines with an immunomodulatory profile, thus favoring the progression of lesions.\textsuperscript{13,21}

**Conclusion**

It is concluded that patients with high-grade lesions have a greater systemic expression of IFN-α and its activation pathways in helper and cytotoxic T lymphocytes, as well as in monocytes, due to an exacerbation of the immune response in these patients. This phenomenon is not accompanied by the resolution of the lesion due to a defect in the IFN-α activation path revealed by the low local expression IFNR1 and high local expression of SOCS1 and SOCS3.

**Conflict of Interests**

The authors have no conflict of interests to declare.

**Acknowledgments**

The present study was supported by the Brazilian National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico), the Foundation for Research Assistance of the State of Minas Gerais (Fundação de Amparo à Pesquisa do Estado de Minas Gerais,) and the Uberaba Teaching and Research Foundation (Fundação de Ensino e Pesquisa de Uberaba).

**Referências**

1. Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016;115(09):1140–1146. Doi: 10.1038/bjc.2016.290
2. Kyrgiou M, Athanasiou A, Kalliara IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PP, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017;11(11):CD012847. Doi: 10.1002/14651858.CD012847
3. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998; 67:227–264. Doi: 10.1146/annurev.biochem.67.1.227
4. Hervás-Stubbs S, Perez-Gracia JL, Rouzaut A, Sannamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011;17(09):2619–2627. Doi: 10.1158/1078-0432.CCR-11-1114
5. Shi WY, Cao C, Liu L. Interferon α induces the apoptosis of cervical cancer hela cells by activating both the intrinsic mitochondrial pathway and endoplasmic reticulum stress-induced pathway. Int J Mol Sci. 2016;17(11):1832. Doi: 10.3390/ijms17111832
6. Pervolaraki K, Rastgouf Taliem S, Albrecht D, Bormann F, Bamford C, Mendoza JL, et al. Differential induction of interferon stimulated genes between type I and type III interferons is independent of interferon receptor abundance. PLoS Pathog. 2018;14(11): e1007420. Doi: 10.1371/journal.ppat.1007420
7. Ousman SS, Wang J, Campbell IL. Differential regulation of interferon regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous system during viral infection. J Virol. 2005;79(12):7514–7527. Doi: 10.1128/JVI.79.12.7514-7527.2005
8. Levy DE, Marié I, Prakash A. Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity. Curr Opin Immunol. 2003;15(01):52–58. Doi: 10.1016/s0952-7915(02)00011-0
9. Yang M, Chen H, Zhou L, Huang X, Su F, Wang P. Identification of SOCS family members with prognostic values in human ovarian cancer. Am J Transl Res. 2020;12(05):1824–1838
10. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 2005;7(03):100–110. Doi: 10.1186/ar1741
11. Severa M, Remoli ME, Giacomini E, Ragimbeau J, Lande R, Uzé G, et al. Differential responsiveness to IFN-α and IFN-β of human mature DC through modulation of IFNAR expression. J Leukoc Biol. 2006;79(06):1286–1294. Doi: 10.1189/jlb.1205742
12. Tirone NR, Peghini BC, Barcelos AC, Murta EF, Michelin MA. Local expression of interferon-alpha and interferon receptors in cervical intraepithelial neoplasia. Cancer Immunol Immunother. 2009;58(12):2003–2010. Doi: 10.1007/s00262-009-0707-6
13. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):22–36. Doi: 10.1002/ijgo.12611
14 Moraga I, Harari D, Schreiber G, Uzé G, Pellegrini S. Receptor density is key to the alpha2/beta interferon differential activities. Mol Cell Biol. 2009;29(17):4778–4787. Doi: 10.1128/MCB.01808-0

15 Marrero-Rodríguez D, Baeza-Xochihua V, Taniguchi-Ponciano K, Huerta-Padilla V, Ponce-Navarrete G, Mantilla A, et al. Interferon epsilon mRNA expression could represent a potential molecular marker in cervical cancer. Int J Clin Exp Pathol. 2018;11(04):1979–1988

16 Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8–32. Doi: 10.1111/j.0105-2896.2004.00204.x

17 Scott ML, Woodby BL, Ulicny J, Raikhy G, Orr AW, Songock WK, et al. Human papillomavirus 16 E5 inhibits interferon signaling and supports episomal viral maintenance. J Virol. 2020;94(02):e01582–e19. Doi: 10.1128/JVI.01582-19

18 Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A. SOCS, inflammation, and cancer. JAK-STAT. 2013;2(03):e24053. Doi: 10.4161/jkst.24053

19 Sarmah N, Baruah MN, Baruah S. Immune modulation in HLA-G expressing head and neck squamous cell carcinoma in relation to human papilloma virus positivity: a study from Northeast India. Front Oncol. 2019;9:58. Doi: 10.3389/fonc.2019.00058

20 Marchetti M, Monier MN, Fradagrada A, Mitchell K, Baychelier F, Eid P, et al. Stat-mediated signaling induced by type I and type II interferons (IFNs) is differentially controlled through lipid microdomain association and clathrin-dependent endocytosis of IFN receptors. Mol Biol Cell. 2006;17(07):2896–2909. Doi: 10.1091/mbc.e06-01-0076

21 Peghini BC, Abdalla DR, Barcelos AC, Teodoro LD, Murta EF, Michelin MA. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Hum Immunol. 2012;73(09):920–926. Doi: 10.1016/j.humimm.2012.06.003